Product Name:Apremilast
CAS:608141-41-9
Molecular formula:C22H24N2O7S
Molecular weight:460.5
Content:99.0%min
Apremilast / CAS No: 608141-41-9
Name: Apremilast
CAS No: 608141-41-9
Alisa: Apremilast (CC-10004) ; Otezla
MF: C22H24N2O7S
MW: 460.50
Description:It's white powder Density: 1.382 g/cm3
Boiling point: 741.342 °C at 760 mmHg
Flash point: 402.149 °CAssay:99.0%min
Usage: Anti psoriatic arthritis ; PDE4 and TNF alpha inhibitorsApremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis.Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.
